###### Strengths and limitations of this study

-   Patients receiving extracorporeal membrane oxygenation (ECMO) experience high rates of nosocomial infection which increase morbidity and mortality but prevalence is not known across Australia and New Zealand.

-   The point prevalence design, incorporating monthly data collection weeks over a 12-month period, will increase sample size of this uncommon treatment, and allow smaller-volume centres to contribute.

-   The study design precludes estimates of nosocomial infection incidence in this population.

-   Due to the relatively uncommon nature of ECMO, there is a possibility that some patients receiving ECMO will not be captured.

-   Results are expected to be hypothesis generating and will lead to targeted interventional trials to reduce infection rates.

Introduction {#s1}
============

Extracorporeal membrane oxygenation (ECMO) provides temporary cardiorespiratory support to critically ill patients when maximal conventional support has failed.[@R1] While ECMO offers patients a chance of overcoming critical illness, it is not without significant risks.[@R1] Nosocomial infection is one of the most frequent and serious complications of ECMO[@R2] and is reported in up to 64% of patients.[@R4] Infections acquired on ECMO are associated with longer periods of mechanical ventilation and ECMO support,[@R2] as well as longer hospital stays[@R4] and increased mortality in the paediatric population.[@R10]

Factors associated with increased infection risk include adult patients,[@R2] severity of underlying illness,[@R4] immunosuppression,[@R11] longer duration of ECMO support[@R2] and intensive care unit (ICU) stay,[@R6] and treatment with Veno-arterial (VA) ECMO.[@R2] The presence of intravascular devices, such as large-bore ECMO cannulae, central venous catheters and intra-arterial lines, could similarly place patients at increased risk of nosocomial infections due to disruption to the skin's protective barrier in addition to potential contamination of the multiple ports of entry on these devices.[@R12] ECMO cannula-related infections are difficult to diagnose, due to the inability to routinely replace and culture ECMO cannulae[@R13]; and the systemic inflammatory response to the extracorporeal circuit itself.[@R15] As a result, ECMO cannula-related infections are likely to be under-diagnosed. Indeed, Messika and colleagues[@R16] suggest that primary bloodstream infection (BSI) with an unidentifiable origin should be considered attributable to ECMO cannulae, particularly in the setting of prolonged ECMO treatment.

Data from single-centre studies report ECMO cannula-related infections in 7%--18% of patients undergoing ECMO,[@R8] with an estimated incidence between 4.8 and 17.2 episodes per 1000 ECMO days.[@R4] Given the high incidence of ECMO cannula-related infection and the difficulty in reliably diagnosing it,[@R17] infection prevention measures are vital. Such measures would include the effective dressing and securement of ECMO cannula to prevent micromotion or pistoning of the cannula and subsequent extrinsic contamination of the insertion point. Extensive research has been undertaken to reduce infection in other intravascular devices through effective dressing and securement,[@R19] but has thus far not occurred in ECMO cannulae. These cannulae are the largest of all intravascular devices with quadruple the rate of infection compared with other vascular devices (4.8 vs 1.2 episodes/1000 ECMO days, respectively)[@R17] and therefore this must be seen as a research priority.

Before targeted interventions are developed and tested to address nosocomial infection, the prevalence of such infections must be properly estimated. Therefore, we propose a point prevalence study across Australia and New Zealand to identify the prevalence of suspected or confirmed nosocomial infection in adult, paediatric and neonatal ECMO patients, with a particular focus on ECMO cannula-related infection; and to investigate clinical practice regarding dressing and securement of ECMO cannula.

Methods and analysis {#s2}
====================

Study design {#s2a}
------------

This project is a prospective, observational point prevalence study and will be conducted in 11 ECMO centres across Australia and New Zealand over a 12-month period. Data will be collected for every ECMO patient meeting study inclusion criteria during 12 prespecified 7 day data collection periods, each separated by \~3--4 weeks. This point prevalence design allows relatively uncommon therapies, such as ECMO, to be captured, while also allowing lower volume ECMO centres the opportunity to participate.

Patient and public involvement {#s2b}
------------------------------

As this study is an initial exploratory study to collect baseline data, there has been no patient or public involvement in the development of this study protocol.

Participants {#s2c}
------------

Adult, paediatric and neonatal patients will be included in this study. No formal sample size calculations were completed for this study due to the exploratory nature of the study design. It is anticipated that each participating centre will recruit at least 10 patients over the 12-month recruitment period, giving an expected overall cohort of 120 patients. Inclusion criteria are (1) patients undergoing ECMO treatment with a circuit that includes a membrane oxygenator and pump and (2) patients decannulated from ECMO treatment within the last 48 hours. Exclusion criteria are (1) patients who have had data captured in a previous data collection period, (2) patients decannulated from ECMO \>48 hours and (3) patients with extracorporeal support that does not include a membrane oxygenator and/or pump. As this study aims to identify the prevalence of hospital-acquired infection, patients will not be required to be free from infection at time of study enrolment.

Outcomes {#s2d}
--------

### Primary outcomes {#s2d1}

1.  Laboratory-confirmed BSI, defined as[@R24]:At least one positive culture with an identifiable pathogen/organism; ORPatient has one of the following signs or symptoms: fever (\>38.0°C), chills or hypotension and at least two positive blood cultures for a common skin contaminant within 48 hours (includes coagulase-negative staphylococci, *Micrococcus* spp, *Propionibacterium acnes*, *Bacillus* spp and *Corynebacterium* spp).

2.  Suspected/probable nosocomial infection, defined as:BSI:Two positive blood cultures for a common skin contaminant from two separate blood samples within the preceding 48 hours (includes coagulase-negative staphylococci, *Micrococcus* spp, *P. acnes*, *Bacillus* spp and *Corynebacterium* spp) without signs or symptoms of infection; ORClinical signs of fever (\>38.0°C), chills, hypotension without positive blood culture and no other identifiable secondary source of infection.Ventilator-associated pneumonia (VAP)[@R25]:New onset purulent secretions or change in sputum colour, odour, quantity or consistency; AND/ORRadiological evidence of new and persistent infiltrates (two or more serial chest X-rays or CT scans with suggestive images of pneumonia), and two of the following with no other recognised source.Fever \>38.0°C, white cell count \<4.0 or \>12.0×10^9^/L, new or increasing vasopressor requirement, increasing ECMO respiratory support suggestive of worsening gas exchange.

Given the lack of consensus on definition of VAP and the complexities of diagnosing the infection in a patient on ECMO, where clinical, biochemical and radiological signs may be confounded due to the extracorporeal circuit, a combination of clinical and laboratory parameters will be used to identify cases of VAP.Urinary tract infection (UTI)[@R24]:Two of the following with no other recognised cause:Fever \>38.0°C, urgency, frequency, dysuria, suprapubic tenderness.AND at least one of the following:Positive dipstick for leucocyte esterase and/or nitrate, pyuria urine specimen with \>10 White Blood Cell (WBC)/mL, organisms seen on Gram stain of unspun urine, at least two urine cultures with repeated isolation of the same uropathogen (Gram-negative bacteria or *Staphylococcus saprophyticus*) with ≥102 colonies/mL in unvoided specimens, ≤10⁵ colonies/mL of a single uropathogen (Gram-negative bacteria or *S. saprophyticus*) when the patient is being treated with effective antimicrobial agents for a UTI.Surgical site infection (SSI)[@R25]---including intravascular device (inclusive of ECMO cannula) localised infection:Infection within 30 days after operation or ECMO cannula or intravascular device insertion and involves incisional skin and subcutaneous tissue and at least one of the following:Purulent drainage with or without laboratory confirmation from the incision/insertion site.Organisms isolated from an aseptically obtained fluid or tissue culture from the incision/insertion site.At least one of the signs or symptoms of infection: pain/tenderness, localised swelling, redness or heat.Diagnosis of superficial incisional SSI or intravascular device insertion site made by surgeon or treating intensivist.

### Special considerations for neonates {#s2d2}

To avoid misdiagnosis, in addition to the above criteria other clinical signs that would be considered relevant are:Fever (\>38°C) or temperature instability (frequent post-set of the incubator) or hypothermia (\<36.5°C).Tachycardia (\>200 beats/min) or new/increased bradycardia (\<80 beats/min).Capillary refilling time \>2 s.New or increased apnoea(s) (\>20 s).Unexplained metabolic acidosis.New-onset hyperglycaemia (\>140 mg/dL).Unstable general condition of the patient.Apathy.Increased oxygen requirement.

Relevant laboratory parameters will include:Raised C reactive protein (\>20 mg/L).Immature/total neutrophil ratio \>0.2.Leucocytes\<5×10^9^/L.Platelets \<100×10^9^/L.[@R24]

### Secondary outcomes {#s2d3}

1.  ECMO cannula dressing and securement practices for each cannula on the point prevalence day, specifically:Insertion site dressing type:Gauze and tape.Semipermeable transparent dressing.Transparent, chlorhexidine gluconate-impregnated dressing.Chlorhexidine gluconate-impregnated disk/sponge covered with transparent dressing.Silver-impregnated dressing.Other.Length of time dressing in situ on study day.Sutures to secure cannula at the insertion site and/or along circuit tubing length.Circuit tubing securement methods:Sutures.Commercial suture-less fixation device.Adhesive bandage or tape.Clipping or taping to a fixed object.Other.Number of circuit tubing fixation points used for each cannula on the point prevalence study day:1 point.2 points.\>2 points.Other.

2.  Presence of local dressing and securement guidelines and compliance of reported cannula dressing and securement methods with these guidelines.

Data collection {#s2e}
---------------

On each study week, trained investigators will screen all ECMO patients for eligibility against the predefined inclusion and exclusion criteria. Using the online database provider Research Electronic Data Capture (REDCap; project-redcap.org), investigators will complete one study-specific electronic case report form per eligible ECMO patient on 1 day during the study week. The data collection tool was pilot tested at the coordinating site prior to use in the larger point prevalence study. Data collected will include patient demographic data; ICU admission and treatment information; ECMO indication, modality and settings; ECMO cannula insertion, dressing and securement data; presence of suspected or confirmed nosocomial infection; and antibiotic therapy. Laboratory samples will be collected and analysed as per local hospital policy, all of which are in accordance with local pathology regulatory bodies.

Each site will keep a recruitment log of all patients screened and studied, and each recruited patient will be entered on REDCap using a unique study number identifier. Recruitment logs will be stored securely by investigators at each site for the purposes of data accountability; will be retained for the appropriate period as per institutional policy; and will not be submitted to the coordinating site. To ensure collected data are consistent across sites, a data dictionary (either adult or paediatric/neonates) will be supplied to study investigators. Additionally, investigators at each site will receive education from the coordinating site regarding data collection methods and how to remit the data securely.

Statistical analysis {#s2f}
--------------------

Data will be checked for discrepancies by a study investigator at the coordinating site, and any queries resolved prior to commencement of data analysis. Statistical analysis will be performed using a proprietary statistical package (STATA V.15.x). Data will be examined in accordance with its type and distribution, with, in the first instance, the use of general data descriptive methods. Mean (SD) will be used for normally distributed data, median (IQR) for non-normal data and proportion (%) for categorical and binary data. To determine prevalence of infection, each positive patient episode will be counted as one infection. Data regarding multiple infections and/or organisms will be collected and presented descriptively. Comparative statistics on non-paired data will be performed using tests appropriate for the type of data. That is, the Student's t-test will be used for normal data, the Wilcoxon rank sum test for non-normal data and χ^2^ and Fisher's exact test for categorical/binary data.

Appropriateness and use of inferential statistical analyses will depend on the final sample size of the cohorts. Initially and where appropriate, detailed inferential analysis will be done using univariate regression techniques. More complex multivariable models will be constructed based on those initial results. Specifically, dichotomous outcome data will be analysed using logistic regression while categorical or continuous data will be analysed using linear regression. Regression diagnostics will be employed to test the adequacy and appropriateness of each model. When present, time to event data will be analysed using a Cox proportional hazards model. The level of significance will be set at p\<0.05 unless otherwise dictated by the analytical techniques, for example, when several statistical tests are performed on the same dataset. In this case, a suitable adjustment in p value will be made (eg, Bonferroni correction).

Ethics and dissemination of results {#s3}
===================================

Low risk ethical approval and a waiver of consent has been provided by the Metro South Hospital and Health Service Human Research Ethics Committee (HREC/17/QPAH/383) for Australian sites. Appropriate site-specific approvals were obtained by all Australian sites. For New Zealand sites, ethics approval was obtained from the Southern Health and Disability Ethics Committee (17/STH/93). Study findings will be presented at national and international assemblies. Results will be published in peer-reviewed journals in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology Statement requirements.

Trial status {#s4}
============

Data collection is ongoing over the 12-month study period and will be complete by March 2019.

Discussion {#s5}
==========

Patients undergoing treatment with ECMO experience high rates of nosocomial infection[@R2] which is associated with increases in mortality,[@R10] duration of ECMO support[@R10] and mechanical ventilation,[@R2] and ICU and hospital lengths of stay.[@R4] This multicentre point prevalence study will provide useful data regarding the prevalence of nosocomial infection, including cannula-related local and bloodstream infections, across Australian and New Zealand ECMO populations. Additionally, it will describe ECMO cannula dressing and securement practices across the region. The results will inform future research initiatives aimed at reducing nosocomial infection rates, for instance, a planned randomised controlled trial investigating the most effective method of dressing and securing peripheral ECMO cannulae to reduce infection and cannula dislodgement. Designing strategies to reduce infection rates in this population must be seen as a clinical and research priority, so that patient outcomes can be optimised and healthcare costs reduced.
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